Overview
PolyPeptide Group AG is a Switzerland-based global leader in the pharmaceutical industry, specializing in the development and manufacturing of peptide-based active pharmaceutical ingredients (APIs). The company operates on a global scale with production facilities in the United States, Europe, and India, offering a comprehensive range of generic and proprietary APIs. PolyPeptide is renowned for its innovative projects, including the production of peptides used in the creation of a wide range of medications, from cancer treatments to diabetes management.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for PolyPeptide Group AG as of 30 June 2025 is 368.85 MM.
- The operating income for PolyPeptide Group AG as of 30 June 2025 is -7.11 MM.
- The net income for PolyPeptide Group AG as of 30 June 2025 is -34.72 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 368.85 | -7.11 | -34.72 |
2025-03-31 | 352.82 | -6.53 | -27.14 |
2024-12-31 | 336.79 | -5.95 | -19.56 |
2024-09-30 | 330.19 | -14.70 | -24.06 |
2024-06-30 | 323.58 | -23.44 | -28.56 |
2024-03-31 | 321.98 | -28.63 | -40.00 |
2023-12-31 | 320.37 | -33.83 | -51.44 |
2023-09-30 | 299.76 | -29.87 | -44.09 |
2023-06-30 | 279.16 | -25.92 | -36.75 |
2023-03-31 | 280.07 | -6.70 | -14.49 |
2022-12-31 | 280.98 | 12.53 | 7.77 |
2022-09-30 | 280.81 | 29.44 | 20.32 |
2022-06-30 | 280.65 | 46.36 | 32.88 |
2022-03-31 | 281.39 | 56.88 | 40.07 |
2021-12-31 | 282.13 | 67.40 | 47.26 |
2021-09-30 | 276.57 | 69.04 | 47.69 |
2021-06-30 | 271.00 | 70.67 | 48.13 |
2021-03-31 | 247.65 | 57.49 | 39.73 |
2020-12-31 | 224.30 | 44.31 | 31.34 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -0.59 | -0.59 |
2024-09-30 | -0.73 | -0.73 |
2024-06-30 | -0.87 | -0.87 |
2024-03-31 | -1.22 | -1.22 |
2023-12-31 | -1.56 | -1.56 |
2023-09-30 | -1.34 | -1.34 |
2023-06-30 | -1.12 | -1.11 |
2023-03-31 | -0.44 | -0.43 |
2022-12-31 | 0.24 | 0.24 |
2022-09-30 | 0.62 | 0.62 |
2022-06-30 | 1.00 | 0.99 |
2022-03-31 | 1.23 | 1.23 |
2021-12-31 | 1.47 | 1.47 |
2021-09-30 | 1.52 | 1.52 |
2021-06-30 | 1.57 | 1.57 |
2021-03-31 | 1.31 | 1.31 |
2020-12-31 | 1.04 | 1.04 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for PolyPeptide Group AG as of 30 June 2025 is 138.58 MM.
- The cash from investing activities for PolyPeptide Group AG as of 30 June 2025 is -109.61 MM.
- The cash from financing activities for PolyPeptide Group AG as of 30 June 2025 is -5.86 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 138.58 | -109.61 | -5.86 |
2025-03-31 | 113.99 | -100.31 | -15.59 |
2024-12-31 | 89.40 | -91.02 | -25.32 |
2024-09-30 | 87.34 | -75.83 | -3.28 |
2024-06-30 | 85.28 | -60.64 | 18.77 |
2024-03-31 | 60.88 | -60.08 | 51.66 |
2023-12-31 | 36.48 | -59.51 | 84.55 |
2023-09-30 | 0.64 | -63.92 | 67.31 |
2023-06-30 | -35.20 | -68.33 | 50.08 |
2023-03-31 | -14.87 | -73.38 | 11.60 |
2022-12-31 | 5.46 | -78.44 | -26.87 |
2022-09-30 | 7.05 | -82.65 | -41.54 |
2022-06-30 | 8.64 | -86.86 | -56.22 |
2022-03-31 | 33.00 | -83.85 | 37.36 |
2021-12-31 | 57.35 | -80.84 | 130.93 |
2021-09-30 | 66.97 | -71.78 | 147.41 |
2021-06-30 | 76.58 | -62.72 | 163.89 |
2021-03-31 | 63.03 | -52.64 | 78.58 |
2020-12-31 | 49.48 | -42.56 | -6.73 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 |
Management Effectiveness
- The roa for PolyPeptide Group AG as of 30 June 2025 is -0.03.
- The roe for PolyPeptide Group AG as of 30 June 2025 is -0.10.
- The roic for PolyPeptide Group AG as of 30 June 2025 is -0.04.
- The croic for PolyPeptide Group AG as of 30 June 2025 is -0.06.
- The ocroic for PolyPeptide Group AG as of 30 June 2025 is 0.19.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.03 | -0.10 | -0.04 | -0.06 | 0.19 |
2025-03-31 | -0.03 | -0.08 | -0.04 | -0.06 | 0.19 |
2024-12-31 | -0.04 | -0.05 | -0.06 | 0.08 | 0.18 |
2024-09-30 | -0.04 | -0.06 | -0.06 | 0.08 | 0.18 |
2024-06-30 | -0.09 | -0.10 | -0.10 | 0.11 | 0.07 |
2024-03-31 | -0.09 | -0.12 | -0.10 | 0.11 | 0.07 |
2023-12-31 | -0.06 | -0.10 | -0.09 | 0.00 | 0.00 |
2023-09-30 | -0.06 | -0.09 | -0.08 | -0.12 | -0.07 |
2023-06-30 | -0.06 | -0.09 | -0.07 | -0.11 | -0.07 |
2023-03-31 | -0.03 | -0.03 | -0.03 | -0.17 | -0.03 |
2022-12-31 | 0.01 | 0.02 | 0.02 | -0.22 | 0.01 |
2022-09-30 | 0.03 | 0.05 | 0.04 | -0.24 | 0.02 |
2022-06-30 | 0.06 | 0.09 | 0.07 | -0.26 | 0.02 |
2022-03-31 | 0.07 | 0.10 | 0.09 | -0.00 | 0.07 |
2021-12-31 | 0.13 | 0.27 | 0.10 | 0.26 | 0.13 |
2021-09-30 | 0.13 | 0.27 | 0.11 | 0.33 | 0.15 |
2021-06-30 | 0.16 | 0.32 | 0.11 | 0.40 | 0.17 |
2021-03-31 | 0.13 | 0.27 | 0.09 | 0.20 | 0.14 |
2020-12-31 | 0.10 | 0.21 | 0.14 | -0.00 | 0.22 |
Gross Margins
- The gross margin for PolyPeptide Group AG as of 30 June 2025 is 0.11.
- The net margin for PolyPeptide Group AG as of 30 June 2025 is -0.06.
- The operating margin for PolyPeptide Group AG as of 30 June 2025 is -0.02.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.11 | -0.06 | -0.02 |
2025-03-31 | 0.11 | -0.06 | -0.02 |
2024-12-31 | 0.05 | -0.09 | -0.07 |
2024-09-30 | 0.05 | -0.09 | -0.07 |
2024-06-30 | 0.01 | -0.16 | -0.11 |
2024-03-31 | 0.01 | -0.16 | -0.11 |
2023-12-31 | 0.01 | -0.13 | -0.13 |
2023-09-30 | 0.01 | -0.13 | -0.13 |
2023-06-30 | 0.01 | -0.13 | -0.13 |
2023-03-31 | 0.10 | -0.05 | -0.04 |
2022-12-31 | 0.19 | 0.03 | 0.04 |
2022-09-30 | 0.25 | 0.07 | 0.10 |
2022-06-30 | 0.32 | 0.12 | 0.15 |
2022-03-31 | 0.33 | 0.14 | 0.19 |
2021-12-31 | 0.36 | 0.17 | 0.22 |
2021-09-30 | 0.36 | 0.17 | 0.24 |
2021-06-30 | 0.37 | 0.18 | 0.26 |
2021-03-31 | 0.35 | 0.16 | 0.23 |
2020-12-31 | 0.33 | 0.14 | 0.20 |
Identifiers and Descriptors
Central Index Key (CIK) |
Industry Groups
SIC 8731 - Commercial Physical and Biological Research |